VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Inclusion Criteria: Male or female subject 18 years or older Diagnosis of B-cell lymphoma (CD20+) of follicular lymphoma (grades 1, 2, and 3) or marginal zone lymphoma (extranodal, nodal, and splenic) Documented relapse or progression following prior anti-neoplastic treatment. At least 1 measurable lymph node mass that is >1.5 cm. No active CNS lymphoma Voluntary consent Exclusion Criteria: Previous treatment with VELCADE Any anti-neoplastic or experimental therapy within 3 weeks before the first dose of study drug. Any treatment with nitrosoureas within 6 weeks before the first dose of study drug. Treatment with Zevalin™ or Bexxar® within 10 weeks before the first dose of study drug. Rituximab, Campath® or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug. Radiation therapy within 3 weeks before the first dose of study drug. Major surgery within 2 weeks before the first dose of study drug. Peripheral neuropathy or neuropathic pain History of allergic reaction attributable to compounds containing boron or mannitol Known anaphylaxis or hypersensitivity to any component of rituximab Diagnosed or treated for a selected malignancies other than NHL within 5 years. Active systemic infection requiring treatment Female subjects must not be pregnant, breast-feeding, or become pregnant during the course of the study. Male subjects who do not agree to use an acceptable method of contraception for the duration of the study Any serious medical or psychiatric illness likely to interfere with participation in this clinical study Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.